Science

SBRT for oligoprogression in HCC, suggested by Nina Niu Sanford

Nina Niu Sanford/utswmed.org

Feb 2, 2025, 04:46

SBRT for oligoprogression in HCC, suggested by Nina Niu Sanford

Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared an article by Boyu Leng, et al. on X:

“We also consider SBRT for oligoprogression in HCC b/c:

high local control.
usually low toxicity.
allows pt to stay on 1st line chemo controlling non-progressive tumors.
saves 2nd line in case of future more widespread disease.

This is a nice paper lending support to that strategy.”

Maintaining first-line therapy plus radiotherapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma.

Authors: Boyu Leng, et al.

SBRT for oligoprogression in HCC, suggested by Nina Niu Sanford

Boyu Leng cancer fight against cancer Global fight against cancer HCC Massachusetts General Hospital oligoprogression OncoDaily Oncology radiation oncology SBRT

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25